Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1971 1
1972 2
1974 1
1975 5
1976 2
1977 5
1978 1
1979 7
1980 12
1981 11
1982 12
1983 10
1984 18
1985 19
1986 18
1987 29
1988 11
1989 26
1990 22
1991 26
1992 19
1993 23
1994 20
1995 32
1996 24
1997 33
1998 32
1999 38
2000 40
2001 31
2002 31
2003 45
2004 46
2005 70
2006 76
2007 62
2008 73
2009 86
2010 86
2011 99
2012 112
2013 117
2014 107
2015 161
2016 155
2017 166
2018 181
2019 197
2020 205
2021 221
2022 239
2023 230
2024 86

Text availability

Article attribute

Article type

Publication date

Search Results

2,994 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for simon weeks
Your search for Simon Weekx retrieved no results
Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial.
Geurts VCM, Voorwerk L, Balduzzi S, Salgado R, Van de Vijver K, van Dongen MGJ, Kemper I, Mandjes IAM, Heuver M, Sparreboom W, Haanen JBAG, Sonke GS, Horlings HM, Kok M. Geurts VCM, et al. Breast. 2023 Aug;70:76-81. doi: 10.1016/j.breast.2023.06.007. Epub 2023 Jun 27. Breast. 2023. PMID: 37393645 Free PMC article. Clinical Trial.
In the phase II MIMOSA-trial, HER2-positive MBC patients were treated with trastuzumab and 750 mg monalizumab every two weeks. Following a Simon's two-stage design, 11 patients were included in stage I of the trial. ...
In the phase II MIMOSA-trial, HER2-positive MBC patients were treated with trastuzumab and 750 mg monalizumab every two weeks. Follow …
SIMON: A Digital Protocol to Monitor and Predict Suicidal Ideation.
Sels L, Homan S, Ries A, Santhanam P, Scheerer H, Colla M, Vetter S, Seifritz E, Galatzer-Levy I, Kowatsch T, Scholz U, Kleim B. Sels L, et al. Front Psychiatry. 2021 Jul 1;12:554811. doi: 10.3389/fpsyt.2021.554811. eCollection 2021. Front Psychiatry. 2021. PMID: 34276427 Free PMC article.
Specifically, two smartphone applications -one for self-reports (SIMON-SELF) and one for passive mobile sensing (SIMON-SENSE)- are installed on participants' smartphones. SIMON-SELF uses a text-based chatbot, called Simon, to guide participants along t …
Specifically, two smartphone applications -one for self-reports (SIMON-SELF) and one for passive mobile sensing (SIMON-SENSE)- …
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
Duvivier HL, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Al Baghdadi T, Alva AS, Dublis SA, Cannon TL, Calfa CJ, Li R, Behl D, Chiu VK, Gold PJ, Marr AS, Mileham KF, Powell SF, Rodon J, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Duvivier HL, et al. J Clin Oncol. 2023 Nov 20;41(33):5140-5150. doi: 10.1200/JCO.23.00702. Epub 2023 Aug 10. J Clin Oncol. 2023. PMID: 37561967
The primary end point was disease control (DC), defined as complete or partial response or stable disease (SD) of at least 16-weeks duration. For the CRC cohort, Simon's two-stage design with a null DC rate of 15% versus 35% (power = 0.85; alpha = .10) was us …
The primary end point was disease control (DC), defined as complete or partial response or stable disease (SD) of at least 16-weeks d …
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial.
Lv Y, Chen H, Luo B, Bai W, Li K, Wang Z, Xia D, Guo W, Wang Q, Li X, Yuan J, Cai H, Xia J, Yin Z, Fan D, Han G. Lv Y, et al. Lancet Gastroenterol Hepatol. 2022 Aug;7(8):736-746. doi: 10.1016/S2468-1253(22)00087-5. Epub 2022 May 17. Lancet Gastroenterol Hepatol. 2022. PMID: 35588750 Clinical Trial.
Eligible patients were aged 18-75 years with cirrhosis and had variceal bleeding in the past 6 weeks, and they were randomly assigned (1:1) to receive TIPS (with a covered stent in both groups) plus variceal embolisation (TIPS plus embolisation group) or TIPS alone (TIPS g …
Eligible patients were aged 18-75 years with cirrhosis and had variceal bleeding in the past 6 weeks, and they were randomly assigned …
Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata.
Woll PJ, Gaunt P, Gaskell C, Young R, Benson C, Judson IR, Seddon BM, Marples M, Ali N, Strauss SJ, Lee A, Hughes A, Kaur B, Hughes D, Billingham L. Woll PJ, et al. Br J Cancer. 2023 Oct;129(9):1490-1499. doi: 10.1038/s41416-023-02416-6. Epub 2023 Sep 8. Br J Cancer. 2023. PMID: 37684354 Free PMC article. Clinical Trial.
Patients were recruited within four tumour strata, each analysed separately: angiosarcoma, leiomyosarcoma, synovial sarcoma, or other eligible STSs. The primary outcome was progression-free survival at 12 weeks (PFS12). A Simon's two-stage design with activit …
Patients were recruited within four tumour strata, each analysed separately: angiosarcoma, leiomyosarcoma, synovial sarcoma, or other eligib …
Effects of 4 Weeks of Active Exergames Training on Muscular Fitness in Elderly Women.
Gallardo-Meza C, Simon K, Bustamante-Ara N, Ramirez-Campillo R, García-Pinillos F, Keogh JWL, Izquierdo M. Gallardo-Meza C, et al. J Strength Cond Res. 2022 Feb 1;36(2):427-432. doi: 10.1519/JSC.0000000000003560. J Strength Cond Res. 2022. PMID: 32483059 Clinical Trial.
Gallardo-Meza, C, Simon, K, Bustamante-Ara, N, Ramirez-Campillo, R, Garcia-Pinillos, F, Keogh, JWL, and Izquierdo, M. Effects of 4 weeks of active exergames training on muscular fitness in elderly women. ...
Gallardo-Meza, C, Simon, K, Bustamante-Ara, N, Ramirez-Campillo, R, Garcia-Pinillos, F, Keogh, JWL, and Izquierdo, M. Effects of 4 …
COVID-19 vaccination mandates and vaccine uptake.
Karaivanov A, Kim D, Lu SE, Shigeoka H. Karaivanov A, et al. Nat Hum Behav. 2022 Dec;6(12):1615-1624. doi: 10.1038/s41562-022-01363-1. Epub 2022 Jun 2. Nat Hum Behav. 2022. PMID: 35654962
Counterfactual simulations using our estimates suggest the following cumulative gains in the vaccination rate among the eligible population (age 12 and over) as of 31 October 2021: up to 5 percentage points (p.p.) (90% confidence interval, 3.9-5.8) for Canadian provinces, adding …
Counterfactual simulations using our estimates suggest the following cumulative gains in the vaccination rate among the eligible population …
Joint Simon effects in extrapersonal space.
Welsh TN, Kiernan D, Neyedli HF, Ray M, Pratt J, Potruff A, Weeks DJ. Welsh TN, et al. J Mot Behav. 2013;45(1):1-5. doi: 10.1080/00222895.2012.746635. Epub 2013 Feb 6. J Mot Behav. 2013. PMID: 23387518
Numerous studies have revealed that when people sit next to each other and complete separate parts of a Simon task, response times are shorter when the participants' stimulus appears in front of them than when the stimulus appears in the opposite side of space. According t …
Numerous studies have revealed that when people sit next to each other and complete separate parts of a Simon task, response times ar …
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study.
Simonelli M, Garralda E, Eskens F, Gil-Martin M, Yen CJ, Obermannova R, Chao Y, Lonardi S, Melichar B, Moreno V, Yu ML, Bongiovanni A, Calvo E, Rottey S, Machiels JP, Gonzalez-Martin A, Paz-Ares L, Chang CL, Mason W, Lin CC, Reardon DA, Vieito M, Santoro A, Meng R, Abbadessa G, Menas F, Lee H, Liu Q, Combeau C, Ternes N, Ziti-Ljajic S, Massard C. Simonelli M, et al. ESMO Open. 2022 Oct;7(5):100562. doi: 10.1016/j.esmoop.2022.100562. Epub 2022 Aug 18. ESMO Open. 2022. PMID: 35987165 Free PMC article. Clinical Trial.
PATIENTS AND METHODS: Phase I assessed safety, tolerability, pharmacokinetics, pharmacodynamics, and the recommended phase II dose (RP2D) of isatuximab 10 mg/kg intravenously (i.v.) every week for 3 weeks followed by once every 3 weeks + atezolizumab 1200 mg i.v. ev …
PATIENTS AND METHODS: Phase I assessed safety, tolerability, pharmacokinetics, pharmacodynamics, and the recommended phase II dose (RP2D) of …
The first 8 weeks of the Austrian SARS-CoV-2 epidemic.
Nagel A, Łaszewska A, Haidinger G, Simon J. Nagel A, et al. Wien Klin Wochenschr. 2021 Apr;133(7-8):364-376. doi: 10.1007/s00508-020-01804-9. Epub 2021 Feb 1. Wien Klin Wochenschr. 2021. PMID: 33523297 Free PMC article.
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reached Austria in February 2020. This study aims to describe the first 8 weeks of the Austrian epidemic and reflect on the potential mental health consequences as known at that time. ...
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reached Austria in February 2020. This study aims to describe the f …
2,994 results